Evidence map›Paper›PMID 31736110›Full record

ReviewJournal of clinical pharmacy and therapeutics2020

HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review.

Zoran Gluvic, Milan Obradovic, Milena Lackovic, Vladimir Samardzic, Jelena Tica Jevtic, Magbubah Essack, Vladimir B Bajic, Esma R Isenovic

Open access · hybridAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical pharmacy and therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Zoran GluvicClinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia.
Milan ObradovicLaboratory for Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.ORCID https://orcid.org/0000-0002-4769-2652
Milena LackovicClinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia.
Vladimir SamardzicClinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia.
Jelena Tica JevticClinic for Internal Medicine, Department of Endocrinology and Diabetes, Zemun Clinical Hospital, School of Medicine, University of Belgrade, Belgrade, Serbia.
Magbubah EssackComputational Bioscience Research Center (CBRC), Computer, Electrical, and Mathematical Sciences and Engineering (CEMSE) Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Vladimir B BajicComputational Bioscience Research Center (CBRC), Computer, Electrical, and Mathematical Sciences and Engineering (CEMSE) Division, King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia.
Esma R IsenovicLaboratory for Radiobiology and Molecular Genetics, Vinca Institute of Nuclear Sciences, University of Belgrade, Belgrade, Serbia.
University of Belgrade · RSKing Abdullah University of Science and Technology · SA

Funding

KAUST OSR#4129KAUST Base Research Fund BAS/1/1606-01-01KAUST Office of Sponsored Research FCC/1/1976-17-01King Abdullah University of Science and Technology BAS/1/1606-01-01King Abdullah University of Science and Technology FCC/1/1976-17-01King Abdullah University of Science and Technology OSR#4129Ministry of Education, Science and Technological Development 173033Ministry of Education, Science and Technological Development, Republic of Serbia 173033
6 · The paper itself

Abstract

WHAT IS KNOWN AND

objectiveThe HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia. CASE DESCRIPTION: A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five-point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge. WHAT IS NEW AND

conclusionIn thalassaemia and haemoglobinopathies, due to discrepancies in the five-point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously.

Indexed as

Agedbeta-ThalassemiaBiomarkersBlood GlucoseDiabetes Mellitus, Type 2Diabetic FootFructosamineGlycated HemoglobinHumansHyperbaric OxygenationHypoglycemic AgentsInsulinMaleBiomarkersBlood GlucoseFructosamineGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsInsulindiabetesfructosamineglycaemic controlglycaemic profileHbA1Cthalassaemia

Identifiers

PMID31736110
PMCPMC7384187
OpenAlexW2986165894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.